An observational study in Heart Failure With Reduced Ejection Fraction, sponsored by University of Leipzig. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by University of Leipzig · Observational
Sacubitril-Valsartan reduced heart failure hospitalizations and cardiovascular mortality compared to enelapril in chronic heart failure. Furthermore, quality of life is improved. The decrease of NT-proBNP levels during Sacubitril-Valsartan treatment is associated with reverse left ventricular remodeling and improved left ventricular systolic function. However, the underlying mechanisms that contribute to these symptomatic and prognostic benefits are largely unknown. The aim of this study is to evaluate left ventricular hemodynamics in patients treated with Sacubitril-Valsartan using non-invasive pressure-volume analysis.
University of Leipzig is the lead sponsor of 147 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with symptomatic heart failure (NYHA functional class II to IV) and reduced ejection fraction (LVEF≤40%) with clinical indication for therapy with Sacubitril-Valsartan
Exclusion Criteria:
Observational study during the clinically indicated treatment
Left ventricular contractility, afterload and ventricular-arterial coupling
Change of end-systolic elastance (Ees), arterial elastance (Ea) and ventricular-arterial coupling (Ea/Ees)
Time frame: 6 months
Systolic and diastolic LV function, symptom status and biomarkers
* Echocardiography: Left ventricular (LV) remodeling und function (LVEDV, LVESV, LVEF, GLS), diastolic LV function (LAESV, E/e', LVEDP) * Symptoms: NYHA functional class, 6 minute walk test * Biomarker: NT-proBNP
Time frame: 3, 6 and 12 months
Left ventricular contractility, afterload and ventricular-arterial coupling
Change of end-systolic elastance (Ees), arterial elastance (Ea) and ventricular-arterial coupling (Ea/Ees)
Time frame: 3 and 12 months
Load-independent parameters of systolic and diastolic LV function, myocardial work indices
* Peak power index (PPI) * Preload-recruitable stroke work (PRSW) * End-systolic meridional wall stress (EsMWS) * Total peripheral resistance (TPR) * LV end-systolic pressure (LVEDP) * LV end-diastolic pressure-volume relationship (LVEDPVR) * Pressure-strain loops
Time frame: 3, 6 and 12 months
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Leipzig